Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Analysis
  4. Fast Track Articles
  5. Fast Track Article
image of Concurrent Estimation of Pregabalin and Etoricoxib by New Stability-Indicating RP-UPLC Approach - Application in Assay of Commercial Tablets

Abstract

Background

The study emphasizes establishing a stability-indicating RP-UPLC method for concurrent estimation of pregabalin and etoricoxib in combined pharmaceutical formulations, confirming effective separation, sensitivity, and repeatability, validated according to ICH guidelines.

Objective

The present research study aims to establish a new stability-indicating RP-UPLC method for concurrently estimating pregabalin and etoricoxib in blended powder and their combined tablet formulation with less run time, high sensitivity, and specificity.

Methods

The effective separation of pregabalin and etoricoxib was achieved with HSS column C18 (150x2.1mm,1.8µm), 0.1% orthophosphoric acid:acetonitrile (65:35 v/v) at a flow rate of 0.3mL/min, and isocratic elution at 228nm. The elution of PRB and ETB was noticed at 1.56 and 2.01 minutes, with good resolution and system suitability with the developed approach.

Results

Pregabalin and etoricoxib have shown linear responses from 18.75 to 112.5µg/mL and 15 to 90µg/mL, respectively. The range of the % RSD for intraday and inter-day precision was 0.33 to 0.81. The LOD and LOQ of pregabalin and etoricoxib were computed to be 0.07 µg/mL and 0.21 µg/mL, and 0.01µg/mL and 0.04 µg/mL, respectively, by standard deviation method. The validation method was carried out using ICH standards. The stability-indicating feature of the method was confirmed by the forced degradation studies where degradants generated by stress testing were clearly distinguished from the peaks of analytes.

Conclusion

The shorter elution period and superior sensitivity of both analytes with this method have been found to be appropriate for regular analysis of pregabalin and etoricoxib.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpa/10.2174/0115734129347947241023103445
2024-10-28
2025-01-22

  • From This Site

    /content/journals/cpa/10.2174/0115734129347947241023103445
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther. Adv. Drug Saf. 2014 5 1 38 56 10.1177/2042098613505614 25083261
    [Google Scholar]
  2. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004 45 Suppl. 6 13 18 10.1111/j.0013‑9580.2004.455003.x 15315511
    [Google Scholar]
  3. Kavoussi R. Pregabalin: From molecule to medicine. Eur. Neuropsychopharmacol. 2006 16 Suppl. 2 S128 S133 10.1016/j.euroneuro.2006.04.005 16765030
    [Google Scholar]
  4. Dworkin R.H. Kirkpatrick P. Pregabalin. Nat. Rev. Drug Discov. 2005 4 6 455 456 10.1038/nrd1756 15959952
    [Google Scholar]
  5. Lauria-Horner B.A. Pohl R.B. Pregabalin: a new anxiolytic. Expert Opin. Investig. Drugs 2003 12 4 663 672 10.1517/13543784.12.4.663 12665421
    [Google Scholar]
  6. Shneker B.F. McAuley J.W. Pregabalin: A new neuromodulator with broad therapeutic indications. Ann. Pharmacother. 2005 39 12 2029 2037 10.1345/aph.1G078 16288079
    [Google Scholar]
  7. Cochrane D.J. Jarvis B. Keating G.M. Etoricoxib. Drugs 2002 62 18 2637 2651 10.2165/00003495‑200262180‑00006 12466002
    [Google Scholar]
  8. Takemoto J.K. Reynolds J.K. Remsberg C.M. Vega-Villa K.R. Davies N.M. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin. Pharmacokinet. 2008 47 11 703 720 10.2165/00003088‑200847110‑00002 18840026
    [Google Scholar]
  9. Dallob A. Hawkey C.J. Greenberg H. Wight N. De Schepper P. Waldman S. Wong P. DeTora L. Gertz B. Agrawal N. Wagner J. Gottesdiener K. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J. Clin. Pharmacol. 2003 43 6 573 585 12817520
    [Google Scholar]
  10. Martina S.D. Vesta K.S. Ripley T.L. Etoricoxib: A highly selective COX-2 inhibitor. Ann. Pharmacother. 2005 39 5 854 862 10.1345/aph.1E543 15827069
    [Google Scholar]
  11. Patrignani P. Capone M.L. Tacconelli S. Clinical pharmacology of etoricoxib: A novel selective COX2 inhibitor. Expert Opin. Pharmacother. 2003 4 2 265 284 12562317
    [Google Scholar]
  12. Kim D.W. Weon K.Y. Pharmaceutical application and development of fixed-dose combination: Dosage form review. J. Pharm. Investig. 2021 51 5 555 570 10.1007/s40005‑021‑00543‑x
    [Google Scholar]
  13. Pregabalin - 5486971. 2004 Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Pregabalin
  14. Yeole A.B. Sree Ranga Lakshmi G. Selvakumar C.J. Goni V.G. Nawal C.L. Valya B.J. Patel B.J. Patel R.D. Pawar E.D. Panigrahi R. Kumar A.Y. Shintre S.S. Devkare P.H. Dharmadhikari S.K. Choudhari S.Y. Doshi M.S. Mehta S.C. Joglekar S.J. Efficacy and safety of pregabalin prolonged release–etoricoxib combination compared to etoricoxib for chronic low back pain: Phase 3, randomized study. Pain Ther. 2022 11 4 1451 1469 10.1007/s40122‑022‑00437‑2 36224489
    [Google Scholar]
  15. Farooqui M.N. Kasawar G.B. Development and validation of HPLC method for the determination of pregabalin in capsules. Indian J. Pharm. Sci. 2010 72 4 517 519 10.4103/0250‑474X.73935 21218069
    [Google Scholar]
  16. Pingale P. Singasane T. Development and validation of HPLC method for the determination of pregabalin in bulk and in pharmaceutical formulations. RJPT. 2012 5 6 829 833
    [Google Scholar]
  17. Martinc B. Roškar R. Grabnar I. Vovk T. Simultaneous determination of gabapentin, pregabalin, vigabatrin, and topiramate in plasma by HPLC with fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2014 962 82 88 10.1016/j.jchromb.2014.05.030 24907547
    [Google Scholar]
  18. Arayne M S. Shahnaz H. Ali A. Sultana N. Monitoring of Pregabalin in pharmaceutical formulations and human serum using UV and RP-HPLC techniques: Application to dissolution test method. Pharm. Anal. Acta 2014 5 2 2 10.4172/2153‑2435.1000287
    [Google Scholar]
  19. Radwan R.A. Abouzied N.F. Badway F.A. New Method Development for Pregabalin Detection in Human Plasma by HPLCDAD. J. Pharm. Appl. Chem. 2020 6 3 61
    [Google Scholar]
  20. Bhatt K.K. Patelia E.M. Mori A. Simultaneous estimation of pregabalin and methylcobalamine in pharmaceutical formulation by RP-HPLC method. J. Anal. Bioanal. Tech. 2013 4 1 1 4
    [Google Scholar]
  21. Kannapan N. Nayak S.P. Venkatachalam T. Prabhakaran V. Analytical RP-HPLC method for development and validation of pregabalin and methylcobalamine in combined capsule formulation. 2010
    [Google Scholar]
  22. Kavitha M.P. Rajasekhar A. A validated HPLC method for the analysis of pregabalin and methylcobalamin in bulk and pharmaceutical formulation. Pharm. Glob. 2013 4 7 1
    [Google Scholar]
  23. Patel H.M. Suhagia B.N. Shah S.A. Rathod I.S. Determination of etoricoxib in pharmaceutical formulations by HPLC method. Indian J. Pharm. Sci. 2007 69 5 703 10.4103/0250‑474X.38485
    [Google Scholar]
  24. Topalli S. Chandrashekhar T.G. Annapurna M.M. Validated RP‐HPLC Method for the Assay of Etoricoxib (A Non‐Steroidal Anti‐Inflammatory Drug) in Pharmaceutical Dosage Forms. J. Chem. 2012 9 2 832 838 10.1155/2012/264567
    [Google Scholar]
  25. Hartman R. Abrahim A. Clausen A. Mao B. Crocker L.S. Ge Z. Development and validation of an HPLC method for the impurity and quantitative analysis of etoricoxib. J. Liq. Chromatogr. Relat. Technol. 2003 26 15 2551 2566 10.1081/JLC‑120023800
    [Google Scholar]
  26. Pattan S.R. Jamdar S.G. Godge R.K. Dighe N.S. Daithankar A.V. Nirmal S.A. Pai M.G. RP-HPLC method for simultaneous estimation of paracetamol and etoricoxib from bulk and tablets. J. Chem. Pharm. Res. 2009 1 1 329 335
    [Google Scholar]
  27. Kumar S. Joshi A. Thakur R.S. Pathak A.K. Shah K. Simultaneous estimation of etoricoxib and thiocolchicoside by RP-HPLC method in combined dosage forms. Acta Pol. Pharm. 2011 68 6 839 843 22125947
    [Google Scholar]
  28. Mandal U. Senthil Rajan D. Bose A. Gowda K.V. Ghosh A. Pal T.K. Development and Validation of an HPLC Method for Analysis of Etoricoxib in Human Plasma. Indian J. Pharm. Sci. 2006 68 4
    [Google Scholar]
  29. Alzweiri M. Sallam M. Al-Zyoud W. Aiedeh K. Stability study of etoricoxib a selective cyclooxygenase-2 inhibitor by a new single and rapid reversed phase HPLC method. Symmetry (Basel) 2018 10 7 288 10.3390/sym10070288
    [Google Scholar]
  30. Loh G.O.K. Wong E.Y.L. Tan Y.T.F. Heng S.C. Saaid M. Cheah K.Y. Mohd Sali N.D. Damenthi N. Ng S.S.M. Ming L.C. Peh K.K. Fast and sensitive HPLC-ESI-MS/MS method for etoricoxib quantification in human plasma and application to bioequivalence study. Molecules 2022 27 17 5706 10.3390/molecules27175706 36080473
    [Google Scholar]
  31. Brum L. Jr Fronza M. Ceni D.C. Barth T. Dalmora S.L. Validation of liquid chromatography and liquid chromatography/tandem mass spectrometry methods for the determination of etoricoxib in pharmaceutical formulations. J. AOAC Int. 2006 89 5 1268 1275 10.1093/jaoac/89.5.1268 17042175
    [Google Scholar]
  32. Karanjkar M.B. Development and validation of RP-HPLC for simultaneous estimation of pregabalin and etoricoxib in pharmaceutical tablet dosage form. IJPSR 2021 13 4 872 879
    [Google Scholar]
  33. Yeluri R.R. Reddy B.S. Kumari R.R. Quantification of pregabalin and etoricoxib combo in tablets and bulk with developed RP-HPLC Method: Stability indicating feature assessment. Int. J. Adv. Sci. Res. 2022 13 04 31 36
    [Google Scholar]
  34. Hanumanth V. Ravi Kumar P. Sravya K. Padmavathi Y. Raghavendra Babu N. Sowmya K. Simultaneous estimation of pregabalin and etoricoxib in bulk and pharmaceutical dosage form by using RP-HPLC method. J. Drug Deliv. Ther. 2023 13 9 20 27 10.22270/jddt.v13i9.6200
    [Google Scholar]
  35. Chaudhary A. Singh B.K. Simultaneous estimation of pregabalin and etoricoxib using novel HPLC method: An application in quantitative analysis of pharmaceutical dosage forms. IJPER 2021 55 3s S837 S843 10.5530/ijper.55.3s.191
    [Google Scholar]
  36. Nováková L. Matysová L. Solich P. Advantages of application of UPLC in pharmaceutical analysis. Talanta 2006 68 3 908 918 10.1016/j.talanta.2005.06.035 18970409
    [Google Scholar]
  37. Ravisankar P. Navya C.N. Pravallika D. Sri D.N. A review on step-by-step analytical method validation. IOSR J. Pharm. 2015 5 10 7 19
    [Google Scholar]
  38. Sharma S. Goyal S. Chauhan K. A review on analytical method development and validation. Int. J. Appl. Pharm. 2018 10 6 8 15 10.22159/ijap.2018v10i6.28279
    [Google Scholar]
  39. Blessy M. Patel R.D. Prajapati P.N. Agrawal Y.K. Development of forced degradation and stability indicating studies of drugs—A review. J. Pharm. Anal. 2014 4 3 159 165 10.1016/j.jpha.2013.09.003 29403878
    [Google Scholar]
  40. Venkataraman S. Manasa M. Forced degradation studies: Regulatory guidance, characterization of drugs, and their degradation products-a review. Drug Invent. Today 2018 10 2
    [Google Scholar]
  41. Kogawa A C. RN Salgado H. Impurities and forced degradation studies: a review. Curr. Pharm. Anal. 2016 12 1 18 24
    [Google Scholar]
  42. Godela R. Gummadi S. Pathak S. Pola K.K. Yagnambhatla R. RP-HPLC–PDA approach for concurrent analysis of telmisartan and azelnidipine in bulk and commercial tablets. Chemistry Africa 2023 6 1 393 403 10.1007/s42250‑022‑00483‑5
    [Google Scholar]
/content/journals/cpa/10.2174/0115734129347947241023103445
Loading
Concurrent Estimation of Pregabalin and Etoricoxib by New Stability-Indicating RP-UPLC Approach - Application in Assay of Commercial Tablets
Bentham Science Publishers ; https://doi.org/10.2174/0115734129347947241023103445
/content/journals/cpa/10.2174/0115734129347947241023103445
/content/journals/cpa/10.2174/0115734129347947241023103445
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: stability indicating ; C18 column ; etoricoxib ; Pregabalin ; RP-UPLC ; isocratic elution

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test